Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorZeiser, Robert
dc.contributor.authorRusso, Domenico
dc.contributor.authorRam, Ron
dc.contributor.authorHashmi, Shahrukh K.
dc.contributor.authorChakraverty, Ronjon
dc.contributor.authorMiddeke, Jan Moritz
dc.contributor.authorMusso, Maurizio
dc.contributor.authorGiebel, Sebastian
dc.contributor.authorUzay, Ant
dc.contributor.authorLangmuir, Peter
dc.contributor.authorHamad, Nada
dc.contributor.authorBurock, Karin
dc.contributor.authorGowda, Maanasa
dc.contributor.authorStefanelli, Tommaso
dc.contributor.authorLee, Stephanie J.
dc.contributor.authorTeshima, Takanori
dc.contributor.authorLocatelli, Franco
dc.date.accessioned2025-10-16T15:11:34Z
dc.date.issued2025
dc.identifier.doi10.1200/JCO-24-02477
dc.identifier.otherWOS:001540760100001
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/4812
dc.publisherLIPPINCOTT WILLIAMS \& WILKINS
dc.sourceJOURNAL OF CLINICAL ONCOLOGY
dc.titleRuxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
dc.typeArticle

Dosyalar

Koleksiyonlar

WOS